TipRanks

Notifications

Tag: PASG

Total 83 Posts

Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Quanterix (QTRXResearch Report), Passage Bio (PASGResearch Report) and Korro Bio (KRROResearch Report) with bullish sentiments.

Quanterix (QTRX)

Canaccord Genuity analyst Kyle Mikson CFA maintained a Buy rating on Quanterix yesterday and set a price target of $32.00. The company’s shares closed last Monday at $22.47.

According to TipRanks.com, CFA has 0 stars on 0-5 stars ranking scale with an average return of -21.4% and a 20.4% success rate. CFA covers the Healthcare sector, focusing on stocks such as NanoString Technologies, Pacific Biosciences, and Castle Biosciences.

Quanterix has an analyst consensus of Strong Buy, with a price target consensus of $31.67, representing a 35.0% upside. In a report issued on March 20, Leerink Partners also maintained a Buy rating on the stock.

See Insiders’ Hot Stocks on TipRanks >>

Passage Bio (PASG)

Canaccord Genuity analyst Whitney Ijem maintained a Buy rating on Passage Bio yesterday and set a price target of $14.00. The company’s shares closed last Monday at $1.35.

According to TipRanks.com, Ijem is a 5-star analyst with an average return of 26.4% and a 60.9% success rate. Ijem covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.

Currently, the analyst consensus on Passage Bio is a Moderate Buy with an average price target of $14.00.

Korro Bio (KRRO)

In a report released yesterday, Kostas Biliouris from BMO Capital reiterated a Buy rating on Korro Bio, with a price target of $120.00. The company’s shares closed last Monday at $73.42, close to its 52-week high of $77.61.

According to TipRanks.com, Biliouris is a 4-star analyst with an average return of 8.9% and a 46.2% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Centessa Pharmaceuticals, and BioMarin Pharmaceutical.

Korro Bio has an analyst consensus of Strong Buy, with a price target consensus of $117.50, which is a 72.8% upside from current levels. In a report issued on March 12, RBC Capital also maintained a Buy rating on the stock with a $70.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on QTRX: